10x Genomics Begins Shipments of Visium Spatial Gene Expression Solution
November 26 2019 - 9:00AM
10x Genomics (Nasdaq: TXG) today announced it has begun shipping
its Visium Spatial Gene Expression Solution. The Visium Spatial
Gene Expression Solution is the first new product to result from
10x Genomics’ acquisition of Sweden’s Spatial Transcriptomics, a
pioneer in the emerging field of spatial genomics. This solution
builds on the foundation of Spatial Transcriptomics’ earlier
product offering, providing researchers with a comprehensive map of
where gene activity is occurring in a tissue specimen.
The Visium Spatial Gene Expression Solution is
the first of multiple assays planned for the company’s new Visium
platform. It has already seen strong demand from customers,
including a significant number of pre-orders from first-time 10x
Genomics customers, as well as from pharmaceutical and
biotechnology companies. Institutions like the New York Genome
Center, Stanford University Genomics Facility and the University of
Southern California (USC) Keck School of Medicine are among the
first customers to receive the product starting today.
While single cell analysis, which is enabled by
10x Genomics’ Next GEM technology, gives researchers the ability to
see what is inside a cell, the Visium platform for spatial
molecular profiling lets researchers see how cells are organized in
relation to one another, allowing for a deeper understanding of
biological systems in both normal and disease states.
“When we acquired Spatial Transcriptomics last
year, it was with the belief our two teams could improve the
resolution, scale and workflow in spatial genomics to rapidly
accelerate our understanding of biology,” said Michael
Schnall-Levin, senior vice president of research and development
and founding scientist at 10x Genomics. “Today’s announcement
furthers our commitment to enable existing and new researchers in
their work and opens new areas in molecular pathology that were not
possible before.”
10x Genomics’ Visium Spatial Gene Expression
Solution represents a significant improvement in resolution over
the prior offering from Spatial Transcriptomics for spatial
molecular profiling. The solution equips scientists in many areas
of biology, including oncology and neuroscience, with the
following:
- Ability to survey hundreds of
thousands of cells in a tissue section simultaneously using total
mRNA spatial gene expression analysis
- Five times more spots within a
capture area (5000) than the prior offering from Spatial
Transcriptomics allowing researchers to map gene expression to
tissue architecture with high spatial resolution
- Reduction in the time involved to
perform an assay from three days to one day over the previous
offering
- Extremely high sensitivity capable
of yielding at least 100,000+ UMI's and thousands of genes per
spot
- Intuitive software for automated
processing of Visium data as well as providing streamlined data
analysis tools for both bioinformatics novices and experts
- The only comprehensive kitted
solution available on the market allowing researchers to perform
gene discovery from total mRNA analysis
"Spatial genomics opens up new possibilities for
bringing microscopic anatomy into the realm of RNA sequencing.
Visium makes it possible to spatially resolve gene expression in a
complex cytoarchitecture through an end-to-end fully kitted
solution with turn-key software, and no need for capital equipment
investment. Scientists at the Lieber Institute for Brain
Development (LIBD) running samples through the Visium solution have
produced incredibly detailed results on the human brain that we did
not think were possible,” said Daniel Weinberger, CEO of the Lieber
Institute for Brain Development (LIBD), a leading neurosciences
research institution.
Dr. Andrew Jaffe, Lead Investigator at LIBD
continued to say, “These rich spatial transcriptome maps produced
by Visium will add another dimension to the growing single nuclei
and single cell RNA-seq datasets to spatially refine the cell types
in the human brain and their subsequent dysregulation in
debilitating brain disorders."
Weinberger added, "We believe this technology
answers important questions in neurology and neuroscience, and
could also reveal novel molecular insights into other common human
diseases with abnormal pathology."
The Visium Spatial Gene Expression Solution is
shipping to customers today. To learn more, please visit
https://www.10xgenomics.com/solutions/spatial-gene-expression/.
About 10x Genomics10x Genomics
is a life science technology company building products to
interrogate, understand and master biology to advance human health.
The company’s integrated solutions include instruments, consumables
and software for analyzing biological systems at a resolution and
scale that matches the complexity of biology. 10x Genomics products
have been adopted by researchers around the world including 93 of
the top 100 global research institutions and 90 percent of the top
20 global pharmaceutical companies, and have been cited in over 570
research papers on discoveries ranging from oncology to immunology
and neuroscience. The company's patent portfolio comprises more
than 650 issued patents and patent applications.
Disclosure Information10x
Genomics uses filings with the Securities and Exchange Commission,
its website (www.10xgenomics.com), press releases, public
conference calls, public webcasts and its social media accounts as
means of disclosing material non-public information and for
complying with its disclosure obligations under Regulation FD.
ContactsMedia:media@10xgenomics.com Investors:investors@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jul 2023 to Jul 2024